High dose daily interferon-alpha induction and secondary adjunction of ribavirin in treatment-naive patients with chronic hepatitis C-Reference-Cited by-同舟云学术

High dose daily interferon-alpha induction and secondary adjunction of ribavirin in treatment-naive patients with chronic hepatitis C

Published:2006-04 Issue:4 Volume:30 Page:525-532
ISSN:0399-8320
Container-title:Gastroentérologie Clinique et Biologique
language:en
Short-container-title:Gastroentérologie Clinique et Biologique

Author:

Wartelle-Bladou Claire,Arpurt Jean-Pierre,Renou Christophe,Pariente Alexandre,Pillon Didier,Nalet Bernard,Picon Magali,Glibert André,Chousterman Michel,Grasset Denis,Morin Thierry,Bernard Pierre,Fischer Daniel,Ramdani Mohamed,Lagier Evelyne,Rotily Michel,Rotily Michel

Publisher

Elsevier BV

Subject

Gastroenterology,General Medicine

Reference25 articles.

1. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19: 1-46.

2. Consensus conference. Treatment of hepatitis C. Gastroenterol Clin Biol 2002; 26: B303-20.

3. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group;McHutchison;N Engl J Med,1998

4. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT);Poynard;Lancet,1998

5. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial;Manns;Lancet,2001

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The use of unequal randomisation in clinical trials — An update;Contemporary Clinical Trials;2015-11

2. Treatment of Erdheim-Chester Disease with Long-Term High-Dose Interferon-α;Seminars in Arthritis and Rheumatism;2012-06

3. Effect of Ribavirin Alone or Combined with Silymarin on Carbon Tetrachloride Induced Hepatic Damage in Rats;Drug Target Insights;2007-01